Emanuela
Emanuela Boschi, Parma IT
Patent application number | Description | Published |
---|---|---|
20110158846 | APPARATUS AND METHOD FOR STERILIZING CONTAINER CLOSURES - An apparatus ( | 06-30-2011 |
Emanuela Branchetti, Philadelphia, PA US
Patent application number | Description | Published |
---|---|---|
20160109458 | METHODS FOR DIAGNOSING AND TREATING BICUSPID AORTIC VALVE AND/OR AORTOPATHIES - Provided herein are methods for identifying and treating BAV disease and/or aortopathy in a subject, and methods of improving outcome in a subject. The subject may be asymptomatic of BAV disease and/or aortopathy, experiencing symptoms of BAV disease and/or aortopathy, have BAV disease and/or aortopathy, or be a blood relative of an individual having BAV disease and/or aortopathy. Levels of sRAGE in the subject's biological sample are determined, compared to a control biological sample, and used as an indicator for the presence and severity of BAV disease and/or aortopathies, a tool to screen family members, and an indicator of the proper surgical or treatment regimens. | 04-21-2016 |
Emanuela Chiappini, Offida (ap) IT
Patent application number | Description | Published |
---|---|---|
20100255326 | PRINTABLE GAS BARRIERS - A method is provided for enhancing the gas barrier properties of substrates such as materials used in packaging, by applying a composition comprising a vinyl alcohol/vinyl amide copolymer, a cross linker and, optionally, a diacrylate or other polyacrylate and a photo initiator to the material and curing the composition by irradiation with UV light, visible light, IR irradiation and/or electron beam or by exposure to heat. The method includes the optional step of subjecting the material to a low-temperature plasma discharge or a corona discharge prior to applying the composition. The method provides, for example, packaging materials, such as, flexible packaging materials such as plastic films producing packaging materials with excellent gas barrier properties, for example oxygen barrier properties, which are readily printed upon. | 10-07-2010 |
Emanuela Dylgjeri, Hatfield, PA US
Patent application number | Description | Published |
---|---|---|
20160051693 | Cellular Delivery of DNA Intercalating Agents - Compositions and methods for targeted delivery of active agents to cells are provided. The compositions comprise a wholly or partially double-stranded synthetic DNA carrier, and an active agent intercalated in double-stranded portions of the DNA carrier. The DNA carrier may also be linked to a targeting agent. The compositions are useful for delivering an active agent into a targeted cell type, for example a cytotoxic agent. | 02-25-2016 |
Emanuela Gancia, Harlow GB
Patent application number | Description | Published |
---|---|---|
20110118230 | DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 05-19-2011 |
20110124654 | DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 05-26-2011 |
20120245144 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE - Benzoxazepin Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 09-27-2012 |
20150087630 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER - Methods of use of compounds of formula (I) for treating cancer: | 03-26-2015 |
20150197529 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS - Compounds of the formula I: | 07-16-2015 |
20150368244 | DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 12-24-2015 |
Emanuela Gancia, Harlow UK
Patent application number | Description | Published |
---|---|---|
20130261104 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER - Methods of use of compounds of formula (I) for treating cancer: | 10-03-2013 |
Emanuela Gancia, Harlow Essex GB
Patent application number | Description | Published |
---|---|---|
20110124622 | ISOINDOLONES DERIVATIVES AS MEK KINASE INHIBITORS AND METHODS OF USE - The invention relates to isoindolones of formula, (I) with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 05-26-2011 |
Emanuela Garcia, Royston GB
Patent application number | Description | Published |
---|---|---|
20090012134 | Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists - Compounds of formula (I): are potent and selective antagonists of the 5-HT | 01-08-2009 |
Emanuela Grassilli, Monza IT
Patent application number | Description | Published |
---|---|---|
20100081704 | MODULATOR COMPOUNDS OF THE DRUG RESISTANCE IN EPITHELIAL TUMOUR CELLS - The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERN1, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells. | 04-01-2010 |
20130041012 | NEW ISOFORM OF BRUTON'S TYROSINE KINASE (BTK) PROTEIN - The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAI, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells. | 02-14-2013 |
20130041013 | ISOFORM OF BRUTON'S TYROSINE KINASE (BTK) PROTEIN - The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells. | 02-14-2013 |
20130041014 | ISOFORM OF BRUTON'S TYROSINE KINASE (BTK) PROTEIN - The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAl, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells. | 02-14-2013 |
20150111953 | Modulator Compounds of Drug Resistance in Epithelial Tumor Cells - The described invention provides a method of treating a patient with an epithelial cancer comprising administering a composition comprising a therapeutic amount of an inhibitor of a BTK protein and one or more chemotherapeutic agent(s) selected from the group consisting of an antimetabolite, a platinum coordination compound, an alkylating agent and a combination thereof, wherein the composition is effective to reduce one or more of tumor cell growth, tumor cell clonogenicity, tumor cell proliferation, tumor cell viability and tumor volume and the therapeutic amount of the inhibitor of a BTK protein and the one or more chemotherapeutic agent(s) exerts a synergistic effect. The described invention also provides methods of treating a chemotherapy drug-resistant cancer and sensitizing a cancer patient to chemotherapy. | 04-23-2015 |
20150150899 | Isoform of Bruton's Tyrosine Kinase (BTK) Protein - The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAI, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumor pathologies. Also described is a method for the determination of the drug resistance in tumor cells, as well as a method for the identification of tumor stem cells. | 06-04-2015 |
Emanuela Izzo, Milano IT
Patent application number | Description | Published |
---|---|---|
20100210631 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly used for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital, and gastrointestinal diseases. | 08-19-2010 |
20110014304 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS - The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the disclosure are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders. | 01-20-2011 |
20130274249 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases. | 10-17-2013 |
20130289122 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases. | 10-31-2013 |
20150157598 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 06-11-2015 |
20150157599 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 06-11-2015 |
20150157600 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 06-11-2015 |
20150157601 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 06-11-2015 |
20150157602 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS - Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) | 06-11-2015 |
Emanuela Licandro, Milano IT
Patent application number | Description | Published |
---|---|---|
20140371463 | BENZODITHIOPHENE DERIVATIVES AND THEIR USE AS PHOTOLUMINESCENT COMPOUNDS - Compound comprising a benzoetherodiazole group of formula (I) and at least one benzodithiophene group or a mixture of compounds comprising a benzoetherodiazole group and at least one benzodithiophene group of formulae (II) and (III). Both said compound and said mixture of compounds can be advantageously used as spectrum converters in luminescent solar concentrators (LSCs), capable, in their turn, of enhancing the performances of solar devices (i.e. devices for exploiting solar energy) such as, for example, photovoltaic cells, photoelectrolytic cells. | 12-18-2014 |
Emanuela Lovati, Mendrisio CH
Patent application number | Description | Published |
---|---|---|
20130231315 | MODIFIED 4-PHENYL-PYRIDINE DERIVATIVES - Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK | 09-05-2013 |
Emanuela Marcenaro, Genova-Pegli IT
Patent application number | Description | Published |
---|---|---|
20090208416 | MONOCLONAL ANTIBODIES AGAINST NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders. | 08-20-2009 |
20110229486 | Monoclonal Antibodies Against NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders. | 09-22-2011 |
20150125464 | MONOCLONAL ANTIBODIES AGAINST NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders. | 05-07-2015 |
20150132316 | MONOCLONAL ANTIBODIES AGAINST NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders. | 05-14-2015 |
Emanuela Martinuzzi, Paris Cedex 14 FR
Patent application number | Description | Published |
---|---|---|
20120094865 | Method for Stimulating Antigen-Specific T Cell Responses Using Accelerated Co-Cultured Dendritic Cells - The invention relates to a method for stimulating antigen-specific T cell responses by using accelerated co-cultured dendritic cells, and to uses thereof, such as a method for diagnosing a disease and a method for producing isolated T cell clones displaying specific immunological properties. | 04-19-2012 |
Emanuela Meiani, Rome IT
Patent application number | Description | Published |
---|---|---|
20090288101 | SERVICE EXCEPTION RESOLUTION FRAMEWORK - A service exception resolution framework provides a centralized exception handling console (EHC) used to reprocess unfulfilled service requests that have result in service request exceptions. The EHC allows an operator to analyze multiple service request exceptions simultaneously from disparate applications and domains. The framework greatly reduces the time, cost, and resource expenditures needed to analyze and resolve service request exceptions and reprocess service requests regardless of the applications and domains from which the service request exceptions result. | 11-19-2009 |
Emanuela Peschechera, Milan IT
Patent application number | Description | Published |
---|---|---|
20100029579 | ANTIVIRAL COMPOUNDS - The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M | 02-04-2010 |
20120269771 | SIALOCHIMERIC COMPOUNDS - The present invention discloses a new class of compounds that exhibit an inhibitory effect on influenza virus type A and B, which may or may not be resistant to other drugs, as well as on other types of viruses, such as flavivirus but also on protozoa and other micro-organisms, their preparation methods, pharmaceutical formulations containing them and their use as medicinal products for the treatment of various conditions caused by particular microorganisms, including viruses, bacteria and protozoa, which affect animal and human health. | 10-25-2012 |
Emanuela Rossito, Saint-Egreve FR
Patent application number | Description | Published |
---|---|---|
20150322366 | Lubricant Coating for Medical Container - The invention relates to a lubricant coating for a medical container comprising a cross-linked lubricant composition comprising a mixture of non-reactive silicone with reactive silicone, characterized in that the reactive silicone comprises a mixture of vinyl-based silicone and acrylate-based silicone. The invention further relates to a lubricant composition usable as an intermediate product in the fabrication of a lubricant coating. The invention further relates to a medical container comprising a barrel and a stopper in gliding engagement within the barrel, comprising such a lubricant coating. The invention also relates to a process of manufacturing a medical container comprising a barrel and a stopper in gliding engagement within the barrel including depositing a lubricant composition on the inner surface of the barrel and/or on the stopper, and irradiating the coated barrel and/or stopper so as to cross-link the lubricant composition to form a lubricant coating. | 11-12-2015 |
Emanuela Scalambra, Ferrara IT
Patent application number | Description | Published |
---|---|---|
20140363386 | DUALISTIC MOLECULES HAVING UV RADIATION FILTRATING ABILITY AT WIDE SPECTRUM AND POTENT DAMPING ACTIVITY OF THE REACTIVITY OF FREE RADICALS (RADICAL SCAVENGING) - Compound with structure 2-phenylbenzimidazole of formula I and/or a pharmaceutically acceptable salt thereof, wherein said compound of formula I corresponds to: | 12-11-2014 |
Emanuela Tassoni, Ciampino IT
Patent application number | Description | Published |
---|---|---|
20090312286 | DERIVATIVES OF 4-TRIMETHYLAMMONIUM-3-AMINOBUTYRATE AND 4-TRIMETHYLPHOSPHONIUM-3-AMINOBUTYRATE AS CPT-INHIBITORS - The invention provides a new class of compounds capable of inhibiting carnitine palmitoyl transferase (CPT) having formula (I) | 12-17-2009 |
20110136905 | CRYSTALLINE TEGLICAR - The present invention relates to a new crystalline form of R-4-trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical compositions containing same. | 06-09-2011 |
Emanuela Troiani, Dublin IE
Patent application number | Description | Published |
---|---|---|
20130290059 | SYSTEM AND METHOD FOR MANAGING SALES MEETINGS - The technology disclosed relates to helping sales engineers prepare for sales meetings. In particular, it relates to intelligently and automatically creating packages of information related to sales meetings. The information packages are stored in on-demand systems that are accessible by a plurality of devices used by the sales engineer. | 10-31-2013 |
Emanuela Voorwinden, Delft NL
Patent application number | Description | Published |
---|---|---|
20150139459 | COMMUNICATION SYSTEM - The present invention regards a communication system ( | 05-21-2015 |
Emanuela Zannin, Milano IT
Patent application number | Description | Published |
---|---|---|
20120266882 | APPARATUS FOR RESPIRATORY SUPPORT AND NON-INVASIVE DETECTION OF ALVEOLAR DERECRUITMENT FOR PATIENTS SUFFERING FROM RESPIRATORY FAILURE - Apparatus for respiratory support and non-invasive detection of alveolar recruitment/derecruitment provides air supply to a patient at a base pressure and an additional pressure which can be varied at a frequency of from 5 to 10 Hz and transducers applied to the conduits supplying air to the patient to send electric signals to a computer to obtain a variable positive end-expiratory pressure and a to obtain an end expiratory resistance at varying values of positive end expiratory pressure and defining the state of pulmonary recruitment as the value of the positive end-expiratory pressure which corresponds to a point of maximum expiratory resistance. | 10-25-2012 |